This session focuses on the essential legal and funding strategies for early-stage biotech startups, emphasizing the importance of intellectual property (IP) management, legal structures, and the role of due diligence in attracting investors. The panel discusses common pitfalls, the significance of contracts, and the challenges of commercializing university IP. They also explore the timing of freedom to operate studies and the evolving landscape of biotech investment.

For this session, the featured guests were:

1. Chyreene Truluck – Partner at Spoor & Fisher, specializing in intellectual property (IP) law and IP management strategies.
2. Dr Vuyisile Phehane – Executive Manager of UJInvnt Pty Ltd, the Intellectual Property (IP) commercialization company of the University of Johannesburg, South Africa
3. Lucie Arntz – Senior Associate at Hogan Lovells, one of the world's top law firms with 2,532 lawyers working from 51 destinations around the globe.

Takeaways

• Intellectual property is crucial for competitive advantage in biotech.
• Startups should consider outsourcing legal services to manage costs.
• Choosing the right legal structure is vital for biotech startups.
• Understanding IP management is essential for attracting funding.
• Collaboration agreements must clearly define IP ownership and rights.
• Due diligence is critical for investors assessing biotech startups.
• Patents provide public protection, while trade secrets require confidentiality.
• Commercialization often requires significant investment beyond R&D costs.
• Startups should be open to acquisition opportunities.
• Timing and strategic planning are key to successful biotech ventures.

In this episode of the Africa Biotech Conversations Podcast, host Adrienne Leussa welcomes Erin Rencken, General Manager of the newly launched OneBio Innovation Center (OBIC) in Cape Town, South Africa.   The special episode features a live recording from the launch event and a detailed discussion about OBIC's mission, offerings, and community-building efforts.   Erin outlines the center's vision to provide biotech startups with essential lab space, equipment, and a collaborative environment. The conversation also highlights the support received from the Technology Innovation Agency (TIA), private sector partners like Eppendorf, and the center's focus on inclusivity and community engagement through initiatives like Biotech and Beers.   The episode emphasizes the center's role in fostering biotech innovation in Africa, offering a world-class facility for emerging entrepreneurs in the field.   00:58 MeetErin Rencken: General Manager of OBIC 03:05 Vision and Goals of OBIC 05:47 Resources and Facilities at OBIC 09:02 Community and Collaboration 11:14 Partnerships and Future Plans 19:06 Inclusivity and Accessibility 21:10 Joining OBIC: Process and Opportunities 25:20 Erin Rencken's Personal Journey and Vision 27:39 Reflecting on the Journey 28:00 Empowering Women in Biotech 29:10 Invitation to OneBio Innovation Center 29:52 Biotech and Beers Event Details 31:49 Introduction to OneBio Innovation Center 32:56 Overview of Lab Facilities 36:53 Community and Office Space 38:10 Acknowledgements and Thank Yous 43:59 Eppendorf's Contribution and Vision 49:14 Honoring Michael Fichardt 50:02 Closing Remarks and Celebration  

In this episode of the "Africa Biotech Conversations" podcast, host Adrienne Leussa interviews Abdulaziz El Gamal, the co-founder and Chief Product Officer of Proteinea. Proteinea, based in Cairo and Boston, is a tech-bio company focused on leveraging AI to develop next-generation biologics, particularly antibodies with enhanced efficacy, safety, and convenience.

Key Points from the Episode:

1. Company Background:

   • Proteinea was founded in early 2020, right before the global pandemic, which influenced its strategic direction and provided a real-time showcase of biotech's potential in health crises.

2. Role of AI in Biotech:

   • Abdulaziz discusses how AI is integral to Proteinea's operations, helping to streamline drug development processes and enabling the creation of more effective therapeutic solutions.

3. Biotech in Africa:

   • The discussion highlights the unique opportunities and challenges of growing the biotech industry in Africa. Abdulaziz emphasizes the potential for innovation despite the lack of a traditional biotech ecosystem, which Proteinea is helping to cultivate.

4. Empowering Local Talent:

   • Proteinea is committed to developing local talent by integrating expertise from the African diaspora and global biotech community, aiming to build a sustainable and innovative biotech hub in Egypt.

5. Gender Equity and Company Culture:

   • The episode also touches on Proteinea's approach to gender balance and inclusivity, noting significant female leadership within the company and a culture that promotes fairness and opportunity for all employees.

6. Future Prospects:

   • Looking forward, Abdulaziz shares his excitement about upcoming partnerships, new AI model releases, and the potential to develop the first fully African-originated drug, marking significant milestones for Proteinea and the African biotech sector.

Overall, the episode paints a hopeful picture of biotech's future in Africa, with Proteinea at the forefront of this transformation, driven by innovative uses of AI, a commitment to local talent, and an inclusive corporate culture.

The LinkedIn Live session, part of the AMA series on "The Art of Valuation," focused on valuation strategies for biotech startups at early and post-Series A stages. Moderated by Dr. Adrienne Leussa, the discussion featured finance experts Olufemi Elegbe, CFA and Sewu-Steve Tawia.

Key highlights included the importance of financial literacy for biotech entrepreneurs, methods for accurately valuing biotech startups, and strategies for enhancing valuation after Series A. The session also emphasized the need for tailored communication when presenting valuations to investors and included practical advice on packaging a compelling narrative.

The session concluded with an interactive Q&A, where participants explored how proper valuation techniques could attract investors, particularly in the African biotech ecosystem. The speakers underscored the significance of financial acumen, transparency, and the right valuation approach to ensure sustainable growth and investor confidence in biotech ventures.

Notable quotes from the session:

• "Proper preparation leads to good results... this is your baby, and you want to get the best value out of it." - Femi Elegbe
• "Compare yourself not just to people around you but globally because Biotech is a global business." - Sewu-Steve Tawia

Takeaways:

• Financial literacy is crucial for biotech entrepreneurs to effectively communicate with investors and understand the financial aspects of their business.
• Valuation is both an art and a science, combining data and modelling to determine the value of a biotech startup.
• Milestones such as passing clinical trials and obtaining regulatory approvals can significantly enhance the valuation of a biotech startup.
• Understanding key financial terms like revenue, EBITDA, and net profit is essential for entrepreneurs to navigate valuation discussions.
• Different valuation methods, such as discounted cash flow and venture capital methods, can be used to determine the value of a biotech startup.
• R&D costs can also be considered in valuation, providing a floor value based on the investment already made. Entrepreneurs should justify their valuations and be transparent about their assumptions.
• Storytelling and showcasing the value proposition are key components of a compelling valuation presentation.
• Packaging the presentation effectively and making it understandable to non-technical audiences is important.
• Women founders should be mindful of undervaluing themselves and capitalise on the opportunity cost of capital.
• Being well-prepared and presenting a strong case for valuation is crucial in attracting investors.

 

In this insightful episode of the "Ask Me Anything" series on funding and investment, the focus was on early-stage biotech entrepreneurs in Africa.

Adrienne was joined by Gian-Marco Melfi, a partner at OneBio Venture Studios, who shared his expertise on the unique challenges and strategies relevant to securing investment in the biotech sector.

The discussion covered the intricacies of biotech investments, including the importance of understanding the investment landscape, targeting the right type of investors (such as angel investors, family offices, and venture capitalists), and leveraging grants and non-dilutive capital in the early stages. Gian-Marco emphasised the significance of building robust networks, the long timelines associated with biotech ventures compared to tech startups, and the critical role of assembling a strong team to enhance a startup's investment appeal.

This episode serves as a crucial guide for biotech entrepreneurs aiming to navigate the complex investment ecosystem and scale their ventures successfully.

 

In this comprehensive session of the ongoing dialogue with African biotech leaders, the focus was on building and maintaining investor relationships.

Joining Adrienne were seasoned experts, including Dr. Vuyisile Phehane and Gian-Marco Melfi, who are regular contributors, along with first-time guests Natasha Drapeau and Frank Schwarz from Cohesion Bureau.

The discussion covered best practices for engaging with investors, emphasising the importance of communication, the strategic presentation of business plans, and the need for biotech startups to clearly articulate their value proposition. The panel also delved into the nuances of investor relations, such as handling communications during challenging times and tailoring pitches to reflect the potential for exits and strategic partnerships.

This session was aimed at enriching participants' understanding of investor dynamics and enhancing their ability to secure and maintain crucial funding relationships.

In this episode of the "Ask Me Anything" series under the Dialogue with African Biotech Leaders, experts Gian-Marco Melfi and Vuyisile Phehane discuss the nuances of funding for biotech startups.

Focusing on the early stages of startup financing, the conversation explores the challenges startups face in securing funding, the importance of aligning with the right investors, and effective strategies for engaging potential backers. Gian-Marco Melfi, from One Bio Venture Studio, emphasises the significance of building strong, capable teams, while Vuyisile Phehane from the Technology Innovation Agency sheds light on governmental support mechanisms and due diligence processes.

This session offers a deep dive into the ecosystem of biotech investments, providing invaluable insights for entrepreneurs looking to navigate the complex landscape of fundraising.

In this first episode of the "Ask Me Anything" (AMA) series focused on Investment Funding for biotech, held live on LinkedIn, we delved into the intricate world of funding for biotech startups.

The session features profound insights from Dr. Vuyisile Phehane, the Executive: Bio-Economy at South Africa's National Technology Innovation Agency (TIA), and Mr. Gian-Marco Melfi, an investment principal at One BioVenture Studio. Together, they explore the diverse sources of funding available to biotech startups in Africa and provide practical advice on navigating the complex investment landscape.

The discussion covers government and private funding, the importance of aligning with the right investors, and leveraging local and global networks to attract investment. The episode is an enlightening guide for biotech entrepreneurs seeking to understand where the funding is and how to successfully secure it.

Welcome to another retrospective episode of the Dialogue with African Biotech Leaders. In this special session, titled "Going Global: Your 2024 Biotech Growth Plan from Africa and Beyond," we explore cutting-edge strategies for biotech leaders aiming for significant growth in the 2024.

This episode is packed with insights from two distinguished speakers:

• Erica Sosnowski: Managing Partner at Sosna and Co, a leading business development firm in the life sciences industry, with a stellar track record of closing over $250 million in deals.
• Jennifer Andrews: CEO of Freshly Marketing, a seasoned marketing strategist with 14 years of experience in the life sciences industry and author of "Scientist to CEO."

Key takeaways from this episode include:

1. Compelling Messaging and Materials: Learn how to create a clear, compelling message and develop professional marketing materials that resonate with your target audience.
2. Digital Media Leverage: Discover the power of digital media in filling your sales pipeline and ensuring consistent lead generation, even when you're busy with R&D.
3. Going Where Your Audience Is: Strategies for identifying and engaging with your ideal customers through the right events, platforms, and channels.

This episode also covers:

• The importance of aligning your marketing and business development efforts for maximum impact.
• Practical tips for optimizing your LinkedIn profile and company page.
• How to effectively use content marketing and social media to boost your visibility and attract potential partners and investors.

Stay Connected: Follow the Dialogue with African Biotech Leaders LinkedIn page for updates on future episodes and events: https://www.linkedin.com/groups/9389009/

 

Welcome to another insightful episode of the Dialogue with African Biotech Leaders. In this episode, we focus on a critical aspect of biotechnology entrepreneurship—funding and investment.

This episode was recorded as a live plenary session at BIO Africa 2023 in Durban, South Africa, and features in-depth discussions on funding challenges and opportunities in the African biotech landscape.

Join our distinguished panelists:

• Dr. Allama Elmehdi: CEO of Prophamedis International from Mauritania, sharing insights on the funding landscape in West Africa, particularly Francophone Africa, and the role of foreign direct investment.
• Ms. Kim Hewlett: Co-founder and CEO of Next Biosciences from South Africa, discussing alternative funding strategies through revenue partnerships and collaborations.
• Mr. Gian-Marco Melfi: Investment Principal at OneBio, the leading venture studio in Africa focused exclusively on life sciences, providing a venture capital perspective on funding biotech ventures.
• Dr. Vuyisile Phehane: Executive for Bioeconomy at the Technology Innovation Agency (TIA), South Africa, presenting the national funding landscape and the importance of de-risking innovations for attracting investors.

Throughout this episode, we explore:

• The current funding ecosystem for African biotech entrepreneurs.
• Key elements investors look for in biotech ventures.
• Strategies for managing growth alongside funding.
• The significance of public-private partnerships in the biotech space.
• Insights into the role of diversity and local manufacturing in sustainable biotech growth.

Stay Connected: Join the Dialogue with African Biotech Leaders LinkedIn page for updates on future episodes and events: https://www.linkedin.com/groups/9389009/

Watch the video of this plenary session on YouTube: https://www.youtube.com/watch?v=0lCqZPl43zE&themeRefresh=1